Oncocyte Corp (OCX)
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenue | 2,138 | 115 | 104 | |
| Cost of revenues | 806 | 43 | 32 | |
| Cost of revenues amortization of acquired intangibles | 7 | 22 | 22 | |
| Gross profit | 1,325 | 50 | 50 | |
| Sales and marketing | 1,206 | 1,043 | 853 | |
| Research and development | 2,924 | 2,817 | 2,453 | |
| General and administrative | 3,115 | 2,565 | 2,407 | |
| Change in fair value of contingent consideration | 879 | 7,140 | -1,031 | |
| Total operating expenses | 8,124 | 13,565 | 4,682 | |
| Loss from operations | -6,799 | -13,515 | -4,632 | |
| Other income, net | 157 | 53 | 110 | |
| Interest expense | -29 | -31 | -8 | |
| Total other income, net | 128 | 22 | 102 | |
| Loss before income taxes | -6,671 | -13,493 | -4,530 | |
| Net loss | -6,671 | -13,493 | -4,530 | |
| Basic eps | -0.26 | -0.98 | -0.36 | |
| Diluted eps | -0.26 | -0.98 | -0.36 | |
| Basic average shares | 25,694,000 | 13,714,000 | 12,870,000 | |
| Diluted average shares | 25,694,000 | 13,714,000 | 12,870,000 | |